Added to YB: 2026-09-18
Pitch date: 2026-09-15
IPHA [neutral]
Innate Pharma S.A.
Author Info
No bio for this author
Company Info
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Market Cap
EUR 145.4M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.54
P/E
-2.81
EV/Sales
14.84
Sector
Biotechnology
Category
special_situation
Biotech Conference Coverage: Week 2, Day 1 — Part 3 - Innate Pharma S.A.
IPHA (quick overview): Innate Pharma is a legitimate catalyst story, with runway into early 2028 after the Sobi partnership and recent equity financing. Year-end PACIFIC-9 PFS data for AstraZeneca-partnered monalizumab and preliminary data from the 76-patient dose escalation of proprietary Nectin-4 ADC IPH4502 could reshape sentiment. However, the case depends on positive monalizumab results, convincing ADC differentiation and timely lacutamab regulatory execution.
Read full article (2 min)